Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Galectin-3 and HFpEF: Clarifying an Emerging Relationship

Author(s): Basil M. Baccouche and Emmajane Rhodenhiser*

Volume 19, Issue 5, 2023

Published on: 20 April, 2023

Article ID: e200323214796 Pages: 8

DOI: 10.2174/1573403X19666230320165821

Price: $65

Abstract

Introduction: HFpEF is one of the leading causes of death whose burden is estimated to expand in the coming decades. This paper examines the relationship between circulating levels of galectin-3, an emerging risk factor for cardiovascular disease, and the clinical diagnosis of HFpEF.

Methods: The authors reviewed peer-reviewed literature and 18 studies met the inclusion criteria. Study characteristics, study outcome definitions, assay characteristics, main findings, and measures of association were tabulated and summarized.

Results: Five studies found significant associations between galectin-3 and HFpEF diagnosis compared to healthy controls, and one did not. Five studies found significant associations between galectin- 3 concentration in circulation and severity of diastolic dysfunction. Three studies found a statistically significant association between circulating galectin-3 and all-cause mortality or rehospitalization. Two studies found levels of circulating galectin-3 to be a statistically significant predictor of later HFpEF onset. Finally, two studies examined whether galectin-3 was associated with incident HFpEF, one found a significant association and the other did not.

Conclusion: Given the paucity of effective therapeutics for HFpEF, galectin-3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.

[1]
Kanukurti J, Mohammed N, Sreedevi NN, et al. Evaluation of galectin-3 as a novel diagnostic biomarker in patients with heart failure with preserved ejection fraction. J Lab Physic 2020; 12(2): 126-32.
[http://dx.doi.org/10.1055/s-0040-1716608] [PMID: 32905127]
[2]
Mitic VT, Stojanovic DR, Deljanin IMZ, et al. Cardiac remodeling biomarkers as potential circulating markers of left ventricular hypertrophy in heart failure with preserved ejection fraction. Tohoku J Exp Med 2020; 250(4): 233-42.
[http://dx.doi.org/10.1620/tjem.250.233] [PMID: 32295985]
[3]
Yin QS, Shi B, Dong L, Bi L. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 2014; 11(1): 79-82.
[PMID: 24748886]
[4]
Polat V, Bozcali E, Uygun T, Opan S, Karakaya O. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol 2016; 71(2): 191-7.
[http://dx.doi.org/10.1080/AC.71.2.3141849] [PMID: 27090041]
[5]
Lebedev DA, Lyasnikova EA, Vasilyeva EY, Babenko AY, Shlyakhto EV. Type 2 diabetes mellitus and chronic heart failure with midrange and preserved ejection fraction: A focus on serum biomarkers of fibrosis. J Diabet Res 2020; 2020: 6976153.
[http://dx.doi.org/10.1155/2020/6976153] [PMID: 33224989]
[6]
Merino-Merino A, Saez-Maleta R, Salgado-Aranda R, et al. Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: Diagnostic application and new cut-off points. Heart Lung 2020; 49(4): 388-92.
[http://dx.doi.org/10.1016/j.hrtlng.2020.02.043] [PMID: 32145960]
[7]
Ansari U, Behnes M, Hoffmann J, et al. Galectin-3 reflects the echocardiographic grades of left ventricular diastolic dysfunction. Ann Lab Med 2018; 38(4): 306-15.
[http://dx.doi.org/10.3343/alm.2018.38.4.306] [PMID: 29611380]
[8]
Wu CK, Su MY, Lee JK, et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep 2015; 5(1): 17007.
[http://dx.doi.org/10.1038/srep17007] [PMID: 26582585]
[9]
Beltrami M, Ruocco G, Dastidar AG, et al. Additional value of galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta 2016; 457: 99-105.
[http://dx.doi.org/10.1016/j.cca.2016.04.007] [PMID: 27067445]
[10]
Wu CK, Su MY, Wu YF, Hwang JJ, Lin LY. Combination of plasma biomarkers and clinical data for the detection of myocardial fibrosis or aggravation of heart failure symptoms in heart failure with preserved ejection fraction patients. J Clin Med 2018; 7(11): 427.
[http://dx.doi.org/10.3390/jcm7110427] [PMID: 30413105]
[11]
Pecherina T, Kutikhin A, Kashtalap V, et al. Serum and echocardiographic markers may synergistically predict adverse cardiac remodeling after ST-segment elevation myocardial infarction in patients with preserved ejection fraction. Diagnostics 2020; 10(5): 301.
[http://dx.doi.org/10.3390/diagnostics10050301] [PMID: 32423119]
[12]
Cui Y, Qi X, Huang A, Li J, Hou W, Liu K. Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction. Med Sci Monit 2018; 24: 5139-46.
[http://dx.doi.org/10.12659/MSM.908840] [PMID: 30039808]
[13]
Yu X, Sun Y, Zhao Y, et al. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J 2015; 56(3): 314-8.
[http://dx.doi.org/10.1536/ihj.14-304] [PMID: 25902879]
[14]
Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: Results from the Aldo- DHF trial. Eur J Heart Fail 2015; 17(2): 214-23.
[http://dx.doi.org/10.1002/ejhf.203] [PMID: 25418979]
[15]
Watson CJ, Gallagher J, Wilkinson M, et al. Biomarker profiling for risk of future heart failure (HFpEF) development. J Transl Med 2021; 19(1): 61.
[http://dx.doi.org/10.1186/s12967-021-02735-3] [PMID: 33563287]
[16]
Berezin AE, Kremzer AA, Martovitskaya YV, Berezina TA, Gromenko EA. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. EBio Medic 2016; 4: 86-94.
[http://dx.doi.org/10.1016/j.ebiom.2016.01.018] [PMID: 26981573]
[17]
de Boer RA, Nayor M, deFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol 2018; 3(3): 215-24.
[http://dx.doi.org/10.1001/jamacardio.2017.4987] [PMID: 29322198]
[18]
Trippel TD, Mende M, Düngen HD, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: Results from the DIAST-CHF study. ESC Heart Fail 2021; 8(2): 829-41.https://easychair.org/smart-program/ISEMPH2019/
[19]
Heron M. Deaths: Leading causes for 2017. Natl Vital Stat Rep 2017; 68(6): 1-77.
[PMID: 32501203]
[20]
Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA 2021; 325(18): 1829-30.
[http://dx.doi.org/10.1001/jama.2021.5469] [PMID: 33787821]
[21]
Baccouche BM, Rhodenhiser E, Patel K, Illindala M, Mangla A, Mahmoud MA. The burden of heart failure with preserved ejection fraction in american women is growing: An epidemiological review. N M J Sci 2022; 55: 10.
[22]
Inamdar A, Inamdar A. Heart failure: Diagnosis, management and utilization. J Clin Med 2016; 5(7): 62.
[http://dx.doi.org/10.3390/jcm5070062] [PMID: 27367736]
[23]
Natterson-Horowitz B, Baccouche BM, Head JM, et al. Did giraffe cardiovascular evolution solve the problem of heart failure with preserved ejection fraction? Evol Med Public Health 2021; 9(1): 248-55.
[http://dx.doi.org/10.1093/emph/eoab016] [PMID: 34447575]
[24]
Baccouche BM, Natterson-Horowitz B. Giraffe myocardial hypertrophy as an evolved adaptation and natural animal model of resistance to diastolic heart failure in humans.Int Soc Evol. Medic Public Health Zurich: Switzerland 2019.https://easychair.org/smart-program/ISEMPH2019/2019-08-15. html#talk:108846
[25]
Paulus WJ. Unfolding discoveries in heart failure. N Engl J Med 2020; 382(7): 679-82.
[http://dx.doi.org/10.1056/NEJMcibr1913825] [PMID: 32053308]
[26]
Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the framingham study. JACC Cardiovasc Imaging 2018; 11(1): 1-11.
[http://dx.doi.org/10.1016/j.jcmg.2017.08.007] [PMID: 28917679]
[27]
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017; 3(1): 7-11.
[http://dx.doi.org/10.15420/cfr.2016:25:2] [PMID: 28785469]
[28]
Ilieșiu AM, Hodorogea AS. Treatment of heart failure with preserved ejection fraction. Adv Exp Med Biol 2018; 1067: 67-87.
[http://dx.doi.org/10.1007/5584_2018_149] [PMID: 29498023]
[29]
Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: An update. Theranostics 2018; 8(3): 593-609.
[http://dx.doi.org/10.7150/thno.22196] [PMID: 29344292]
[30]
Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med 2018; 41(2): 599-614.
[PMID: 29207027]
[31]
Baccouche BM. A Mahmoud M, Nief C, Patel K, Natterson-Horowitz B. Galectin-3 is associated with heart failure incidence: A meta-analysis. Curr Cardiol Rev 2022; 19: 1-1.
[PMID: 36397629]
[32]
Howard BE, Phillips J, Miller K, et al. SWIFT-review: A text-mining workbench for systematic review. Syst Rev 2016; 5(1): 87.
[http://dx.doi.org/10.1186/s13643-016-0263-z] [PMID: 27216467]
[33]
Baccouche BM, Shivkumar TE. Using SWIFT-review as a new and robust tool for comprehensive systematic review N M J Sci 2020; 54(1): 14-20.https://www.nmas.org/wp-content/uploads/2021/12/nmjs-54.1-baccouche2.pdf
[34]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372(71): n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[35]
Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol 2019; 46(3): 197-203.
[http://dx.doi.org/10.1111/1440-1681.13048] [PMID: 30372548]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy